Buerger’s disease or thromboangiitis obliterans causes pain, ulceration, or gangrene in the lower or upper extremity. It is associated with chronic cigarette smoking and is believed to be an immune mediated vasculitis. The pathogenesis is still unknown but recent postulate of its association with odontal bacteria has generated much renewed interest. Despite its recognition more than a century ago, little progress has been made in its treatment. Until the pathogenesis is elucidated, abstinence from cigarette is the only effective therapy.
BuergerL. The Circulatory Disturbances of the Extremities. Philadelphia, PA: W.B. Saunders; 1924.
2.
MillsJLTaylorLMJrPorterJM. Buerger’s disease in the modern era. Am J Surg. 1987;154:123-129.
3.
LieJT. The rise and fall and resurgence of thromboangiitis obliterence (Buerger’s disease). Pathol Int. 1989;39:153-158.
4.
MatsushitaMNishikimiNSakuraiTNimuraY. Decrease in prevalence of Buerger’s disease in Japan. Surgery. 1998;124:498-502.
5.
LieJT. Diagnostic histopathology of major systemic and pulmonary vasculitic syndromes. Rheum Dis Clin North Am. 1990;16:269-292.
6.
LeuHJ. Early inflammatory changes in thromboangiitis obliterans. Pathol Microbiol (Basel). 1975;43:151-156.
7.
ShionoyaS. Diagnostic criteria of Buerger’s disease. Int J Cardiol. 1998;1:243-245.
8.
OlinJW. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med. 2000;343:864-869.
9.
MillsJLPorterJM. Buerger’s disease: a review and update. Semin Vasc Surg. 1993;6:14-23.
10.
OlinJWYoungJRGraorRARuschhauptWFBartholomewJR. The changing clinical spectrum of thromboangiitis obliterans (Buerger’s disease). Circulation. 1990;82(5 suppl):IV3-IV8.
11.
WesslerSMingSCGurewichVFreimanDG. A critical evaluation of thromboangiitis obliterans. The case against Buerger’s disease. N Engl J Med. 1960;262:1149-1160.
12.
KobayashiMItoMNakagawaANishikimiNNimuraY. Immununohistochemical analysis of arterial wall cellular infiltration in Buerger’s disease (endarteritis obliterans). J Vasc Surg. 1999;29:452-458.
13.
AdarRPapaMZHalpemZ. Cellular hypersensitivity to collagen in thromboangiitis obliterans. N Engl J Med. 1983;308:1113-1116.
14.
EichhornJSimaDLindschauC. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci. 1998;315:17-23.
15.
CunninghamMW. T cell mimicry in inflammatory heart disease. Mol Immunol. 2004;40:1121-1127.
16.
IwaiTInoueYUmedaM. Oral bacteria in the occluded arteries of patients with Buerger’s disease. J Vasc Surg. 2005;42:107-115.
17.
LiXIwaiTNakamuraH. An ultrastructural study of Porphyromonas gingivalis induced platelet aggregation. Thromb Res. 2008;122:810-819.
18.
IwaiTUmedaMInoueY; Tokyo Medical and Dental University Buerger Disease Research Group. Pathogenic mechanism of the artery and the vein in Buerger’s disease: our hypothesis. Angiology. 2014;2:131. doi:10.4172/2329-9495.1000131.
19.
IwaiTSatoSKumeH. Clinical study of phlebitis migrans and incompetence of the leg’s superficial vein in Buerger’s disease. Ann Vasc Surg. 2012;5:45-51.
20.
DiehmCStammlerF. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med. 2001;344:230-231.
21.
Di MiccoPDi FioreRDi MiccoG. Buerger’s disease and hyperhomocysteinemia: is there a relationship?Open Athero Thromb J. 2008;1:6-8.
22.
FiessingerJNSchaferM. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO study. Lancet. 1990;335:555-557.
23.
The European TAO Study Group. Oral iloprost in the treatment of thromboangiitis obliterans (Buerger’s disease): a double-blind, randomized, placebo-controlled trial. Eur J Vasc Endovasc Surg. 1998;15:300-307.
24.
DeanSMSatianiB. Three cases of digital ischemia successfully treated with cilostazol. Vasc Med. 2001;6:245-248.
25.
De HaroJAcinFBledaSVarelaCEsparzaL. Treatment of thromboangiitis obliterans (Buerger’s disease) with bosentan. BMC Cardiovasc Disord. 2012;12:5.
26.
SayinABozkurtAKTüzünHVuralFSErdogGOaerM. Surgical treatment of Buerger’s disease: experience with 216 patients. Cardiovasc Surg. 1993;1:377-380.
27.
SasajimaTKuboYInabaMGohKAzumaN. Role of infrainguinal bypass in Buerger’s disease: an eighteen-year experience. Eur J Vasc Endovasc Surg. 1997;13:186-192.
28.
LauHChengSW. Buerger’s disease in Hong Kong: a review of 89 cases. Aust NZ J Surg. 1997;67:264-269.
29.
WataridaSShiraishiSFujimuraM. Laparoscopic lumbar sympathectomy for lower-limb disease. Surg Endosc. 2002;16:500-503.
30.
De GiacomoTRendinaEAVenutaF. Thoracoscopic sympathectomy for symptomatic arterial obstruction of the upper extremities. Ann Thorac Surg. 2002;74:885-888.
31.
IsnerJMBaumgartnerIRauhG. Treatment of thromboangiitis obliterans (Buerger’s disease) by intramuscular gene transfer of endothelial growth factor: preliminary clinical results. J Vasc Surg. 1998;28:964-973.
32.
DurduSAkarARAratMSancakTErenNTOzyurdaU. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J Vasc Surg. 2006;44:732-739.
33.
MatobaSTatsumiTMuroharaT. Long term outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation–TACT trial) in patients with chronic limb ischemia. Am Heart J. 2008;156:1010-1018.
34.
MiyamotoKNishigamiKNagayaN. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation. 2006;114:2679-2684.
